CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a sale of company stock on October 14, 2024. The transaction involved the disposal of 4,293 shares of common stock at a price of $46.28 per share, resulting in a total market value of $198,680.04. This sale followed an acquisition of 8,333 shares through the exercise of derivative securities on October 13, 2024. After these transactions, Kulkarni holds a direct beneficial ownership of 226,540 shares. Additionally, Kulkarni has an indirect beneficial ownership of 85,622 shares through The Kulkarni 2023 GRAT. The transactions were reported as completed and took place within a two-day period, from October 13 to October 14, 2024.

CRISPR Therapeutics AG's CEO, Samarth Kulkarni, completed a sale of company stock on October 14, 2024. The transaction involved the disposal of 4,293 shares of common stock at a price of $46.28 per share, resulting in a total market value of $198,680.04. This sale followed an acquisition of 8,333 shares through the exercise of derivative securities on October 13, 2024. After these transactions, Kulkarni holds a direct beneficial ownership of 226,540 shares. Additionally, Kulkarni has an indirect beneficial ownership of 85,622 shares through The Kulkarni 2023 GRAT. The transactions were reported as completed and took place within a two-day period, from October 13 to October 14, 2024.